Benzinga Pro Headlines
Headlines
UBS Maintains Buy on Acadia Healthcare Co, Lowers Price Target to $24
UBS analyst Andrew Mok maintains Acadia Healthcare Co (NASDAQ:ACHC) with a Buy and lowers the price target from $28 to $24.
Morgan Stanley Downgrades Regeneron Pharmaceuticals to Equal-Weight, Maintains Price Target to $767
Morgan Stanley analyst Matthew Harrison downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Overweight to Equal-Weight and maintains the price target from $767 to $767.
UBS Maintains Buy on Signet Jewelers, Raises Price Target to $115
UBS analyst Mauricio Serna maintains Signet Jewelers (NYSE:SIG) with a Buy and raises the price target from $110 to $115.
UBS Maintains Sell on Pure Storage, Raises Price Target to $60
UBS analyst David Vogt maintains Pure Storage (NYSE:PSTG) with a Sell and raises the price target from $55 to $60.
Park Dental Partners Shares Open For Trade At $13/Share; IPO Priced At $13/Share On 1.535M Shares
UBS Maintains Neutral on Oklo, Raises Price Target to $95
UBS analyst Jon Windham maintains Oklo (NYSE:OKLO) with a Neutral and raises the price target from $65 to $95.
UBS Maintains Neutral on Liberty Global, Raises Price Target to $12.6
UBS analyst Polo Tang maintains Liberty Global (NASDAQ:LBTYA) with a Neutral and raises the price target from $11.8 to $12.6.
UBS Maintains Neutral on Designer Brands, Raises Price Target to $4.5
UBS analyst Jay Sole maintains Designer Brands (NYSE:DBI) with a Neutral and raises the price target from $4 to $4.5.
Live On CNBC, U.S. Secretary of Commerce is Howard Lutnick Says We're Investing In Companies That Will Advance Manufacturing In America; xLight Is Trying To Augment Chip Manufacturing
UBS Maintains Buy on CrowdStrike Holdings, Raises Price Target to $590
UBS analyst Roger Boyd maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Buy and raises the price target from $580 to $590.
UBS Maintains Neutral on Ameresco, Raises Price Target to $40
UBS analyst Jon Windham maintains Ameresco (NYSE:AMRC) with a Neutral and raises the price target from $23 to $40.
UBS Maintains Buy on American Eagle Outfitters, Raises Price Target to $31
UBS analyst Jay Sole maintains American Eagle Outfitters (NYSE:AEO) with a Buy and raises the price target from $22 to $31.
Live On CNBC, U.S. Secretary of Commerce is Howard Lutnick Says EU Tech Rules Are Costing Them Big Time; European Economies Are Attacking AI Development With Rules
Deutsche Bank Maintains Hold on Albemarle, Raises Price Target to $125
Deutsche Bank analyst Corinne Blanchard maintains Albemarle (NYSE:ALB) with a Hold and raises the price target from $110 to $125.
Deutsche Bank Maintains Buy on Marvell Tech, Raises Price Target to $125
Deutsche Bank analyst Ross Seymore maintains Marvell Tech (NASDAQ:MRVL) with a Buy and raises the price target from $90 to $125.
Deutsche Bank Maintains Buy on Acadia Healthcare Co, Lowers Price Target to $20
Deutsche Bank analyst Pito Chickering maintains Acadia Healthcare Co (NASDAQ:ACHC) with a Buy and lowers the price target from $33 to $20.
USA Total Vehicle Sales For November 15.60M Vs 15.40M Est.
ISM Non-Manufacturing Business Activity For November 54.5 Vs 54.3 Prior
ISM Non-Manufacturing Employment For November 48.9 Vs 48.2 Prior
ISM Non-Manufacturing Prices For November 65.4 Vs 70.0 Prior
ISM Non-Manufacturing PMI For November 52.6 Vs 52.0 Est.
Canaccord Genuity Maintains Hold on CrowdStrike Holdings, Raises Price Target to $515
Canaccord Genuity analyst Kingsley Crane maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Hold and raises the price target from $500 to $515.
Canaccord Genuity Maintains Buy on GitLab, Maintains $70 Price Target
Canaccord Genuity analyst Kingsley Crane maintains GitLab (NASDAQ:GTLB) with a Buy and maintains $70 price target.
DevvStream Shares Halted On Circuit Breaker To The Downside, Stock Now Up 6.81%
B of A Securities Maintains Neutral on Old Dominion Freight Line, Raises Price Target to $149
B of A Securities analyst Ken Hoexter maintains Old Dominion Freight Line (NASDAQ:ODFL) with a Neutral and raises the price target from $147 to $149.
Canaccord Genuity Maintains Buy on Okta, Maintains $120 Price Target
Canaccord Genuity analyst Kingsley Crane maintains Okta (NASDAQ:OKTA) with a Buy and maintains $120 price target.
Live At The DealBook Summit, U.S. Treasury's Bessent Say Trump Accounts Are The Beginning Of A Shareholder Economy; Trump Accounts Are Aimed At Making Young People Shareholders
Scotiabank Maintains Sector Perform on Okta, Lowers Price Target to $85
Scotiabank analyst Patrick Colville maintains Okta (NASDAQ:OKTA) with a Sector Perform and lowers the price target from $105 to $85.
Scotiabank Maintains Sector Perform on Laurentian Bank of Canada, Raises Price Target to C$40.5
Scotiabank analyst Mike Rizvanovic maintains Laurentian Bank of Canada (TSX:LB) with a Sector Perform and raises the price target from C$33 to C$40.5.
B of A Securities Maintains Underperform on American Eagle Outfitters, Raises Price Target to $18
B of A Securities analyst Christopher Nardone maintains American Eagle Outfitters (NYSE:AEO) with a Underperform and raises the price target from $11 to $18.
Scotiabank Maintains Sector Perform on Groupe Dynamite, Raises Price Target to C$73
Scotiabank analyst John Zamparo maintains Groupe Dynamite (TSX:GRGD) with a Sector Perform and raises the price target from C$49 to C$73.
Scotiabank Maintains Sector Perform on Gibson Energy, Raises Price Target to C$26
Scotiabank analyst Robert Hope maintains Gibson Energy (TSX:GEI) with a Sector Perform and raises the price target from C$25 to C$26.
Scotiabank Maintains Sector Outperform on CrowdStrike Holdings, Raises Price Target to $613
Scotiabank analyst Patrick Colville maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Sector Outperform and raises the price target from $600 to $613.
Live At The DealBook Summit, U.S. Treasury's Bessent Says Growth In Private Credit Is Due To Too-tight Regulation Of Banking System; Trump Administration Regulatory Changes Will Unlock $2.5 Trillion More In Lending Capacity From Banks; Reliance On Private Credit Would Be Procyclical In A Downturn; Private Investors In Lending Will Always Panic At The Bottom
Wells Fargo Maintains Overweight on Marvell Tech, Raises Price Target to $135
Wells Fargo analyst Aaron Rakers maintains Marvell Tech (NASDAQ:MRVL) with a Overweight and raises the price target from $90 to $135.
Capricor Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 440.88%
Wells Fargo Maintains Equal-Weight on GitLab, Lowers Price Target to $45
Wells Fargo analyst Ryan Macwilliams maintains GitLab (NASDAQ:GTLB) with a Equal-Weight and lowers the price target from $50 to $45.
B of A Securities Maintains Buy on Amazon.com, Raises Price Target to $303
B of A Securities analyst Justin Post maintains Amazon.com (NASDAQ:AMZN) with a Buy and raises the price target from $272 to $303.
S&P Global Composite PMI For November 54.2 Vs 54.8 Est.
S&P Global Services PMI For November 54.1 Vs 55.0 Est.
Black Diamond Therapeutics Shares Resume Trade Following Circuit Breaker Halt
Coincheck Group Shares Resume Trade Following Circuit Breaker Halt
Wells Fargo Maintains Equal-Weight on United Natural Foods, Raises Price Target to $37
Wells Fargo analyst Edward Kelly maintains United Natural Foods (NYSE:UNFI) with a Equal-Weight and raises the price target from $36 to $37.
Wells Fargo Maintains Overweight on Monster Beverage, Raises Price Target to $83
Wells Fargo analyst Chris Carey maintains Monster Beverage (NASDAQ:MNST) with a Overweight and raises the price target from $75 to $83.
Wells Fargo Maintains Equal-Weight on Signet Jewelers, Lowers Price Target to $90
Wells Fargo analyst Ike Boruchow maintains Signet Jewelers (NYSE:SIG) with a Equal-Weight and lowers the price target from $100 to $90.
Q/C Technologies Shares Resume Trade Following Circuit Breaker Halt
Wells Fargo Maintains Overweight on Ralph Lauren, Raises Price Target to $385
Wells Fargo analyst Ike Boruchow maintains Ralph Lauren (NYSE:RL) with a Overweight and raises the price target from $345 to $385.
B of A Securities Downgrades Acadia Healthcare Co to Underperform, Lowers Price Target to $13
B of A Securities analyst Kevin Fischbeck downgrades Acadia Healthcare Co (NASDAQ:ACHC) from Neutral to Underperform and lowers the price target from $21.5 to $13.
Capricor Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 534.75%
Wells Fargo Initiates Coverage On Oracle with Overweight Rating, Announces Price Target of $280
Wells Fargo analyst Michael Turrin initiates coverage on Oracle (NYSE:ORCL) with a Overweight rating and announces Price Target of $280.
Capricor Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 452.20%
William Blair Initiates Coverage On Viridian Therapeutics with Outperform Rating
William Blair analyst Lachlan Brown initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Outperform rating.
Live At The DealBook Summit, U.S. Treasury's Bessent Says We Can Recreate Exact Tariff Structure With Other Authorities If SCOTUS Strikes Down IEEPA Tariffs
Live At The DealBook Summit, U.S. Treasury's Bessent Says Supreme Court Needs To Be Prudent About Undoing Trump's International Emergency Economic Powers Act Tariffs; I Am Optimistic On Supreme Court Tariff Decision
Live At The DealBook Summit, U.S. Treasury's Bessent Says Tariffs Have Not Set Off An Inflationary Mindset; China Has Consistently Cut Prices For Exports; I Don't Believe Tariffs Are A Tax
Live At The DealBook Summit, U.S. Treasury's Bessent Says Trump Has Normalized The Idea Of A 15-20% Tariff; I've Evolved On The Idea Of Tariffs
https://www.nytimes.com/live/2025/12/03/business/dealbook-summit-news
'TikTok to Invest More Than $37 Billion in Brazil Data Center' - Bloomberg
William Blair Upgrades Driven Brands Hldgs to Outperform
William Blair analyst Sharon Zackfia upgrades Driven Brands Hldgs (NASDAQ:DRVN) from Market Perform to Outperform.
UBS Initiates Coverage On Roblox with Neutral Rating, Announces Price Target of $103
UBS analyst Christopher Schoell initiates coverage on Roblox (NYSE:RBLX) with a Neutral rating and announces Price Target of $103.
B of A Securities Maintains Buy on ASML Holding, Raises Price Target to $1331
B of A Securities analyst Didier Scemama maintains ASML Holding (NASDAQ:ASML) with a Buy and raises the price target from $1092 to $1331.
UBS Initiates Coverage On Casey's General Stores with Neutral Rating, Announces Price Target of $600
UBS analyst Mark Carden initiates coverage on Casey's General Stores (NASDAQ:CASY) with a Neutral rating and announces Price Target of $600.
BioNTech Minimum Condition in CureVac Exchange Offer Has Been Satisfied
'Microsoft Lowers AI Software Sales Quotas as Customers Resist Newer Products' - The Information
BMO Capital Maintains Market Perform on Monster Beverage, Raises Price Target to $73
BMO Capital analyst Andrew Strelzik maintains Monster Beverage (NASDAQ:MNST) with a Market Perform and raises the price target from $53 to $73.
BMO Capital Maintains Outperform on CrowdStrike Holdings, Raises Price Target to $555
BMO Capital analyst Keith Bachman maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Outperform and raises the price target from $500 to $555.
Ladenburg Thalmann Initiates Coverage On CBL & Associates with Buy Rating, Announces Price Target of $45
Ladenburg Thalmann analyst Floris Van Dijkum initiates coverage on CBL & Associates (NYSE:CBL) with a Buy rating and announces Price Target of $45.
LifeSci Capital Initiates Coverage On Oculis Holding with Outperform Rating, Announces Price Target of $55
LifeSci Capital initiates coverage on Oculis Holding (NASDAQ:OCS) with a Outperform rating and announces Price Target of $55.
BMO Capital Maintains Market Perform on Okta, Lowers Price Target to $90
BMO Capital analyst Keith Bachman maintains Okta (NASDAQ:OKTA) with a Market Perform and lowers the price target from $112 to $90.
BMO Capital Maintains Outperform on Amgen, Raises Price Target to $372
BMO Capital analyst Evan David Seigerman maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $335 to $372.
Barclays Reinstates Overweight on Capri Holdings, Announces $31 Price Target
Barclays analyst Adrienne Yih reinstates Capri Holdings (NYSE:CPRI) with a Overweight and announces $31 price target.
BMO Capital Upgrades Equinix to Outperform, Maintains Price Target to $900
BMO Capital analyst Ari Klein upgrades Equinix (NASDAQ:EQIX) from Market Perform to Outperform and maintains the price target from $900 to $900.
Leerink Partners Downgrades Applied Therapeutics to Market Perform, Lowers Price Target to $1
Leerink Partners analyst Joseph Schwartz downgrades Applied Therapeutics (NASDAQ:APLT) from Outperform to Market Perform and lowers the price target from $2 to $1.
Baird Maintains Outperform on Donaldson, Raises Price Target to $96
Baird analyst Richard Eastman maintains Donaldson (NYSE:DCI) with a Outperform and raises the price target from $85 to $96.
Nixxy Inc. Says Monthly Revenue Run-Rate Increased To Over $15M In Nov. 2025
Baird Maintains Neutral on Leslies, Lowers Price Target to $3
Baird analyst Peter Benedict maintains Leslies (NASDAQ:LESL) with a Neutral and lowers the price target from $6.5 to $3.
Leerink Partners Upgrades Spruce Biosciences to Outperform, Announces $160 Price Target
Leerink Partners analyst Joseph Schwartz upgrades Spruce Biosciences (NASDAQ:SPRB) from Market Perform to Outperform and announces $160 price target.
Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14
Leerink Partners analyst Joseph Schwartz upgrades Design Therapeutics (NASDAQ:DSGN) from Market Perform to Outperform and raises the price target from $7 to $14.
Leerink Partners Downgrades InflaRx to Market Perform, Lowers Price Target to $2
Leerink Partners analyst Joseph Schwartz downgrades InflaRx (NASDAQ:IFRX) from Outperform to Market Perform and lowers the price target from $5 to $2.
Cardio Diagnostics Announces Centers for Medicare and Medicaid Services Issued Final Gapfill Payment Rate Of $854 For Epi+Gen CHD And PrecisionCHD Tests
Lantern Pharma Reports Additional LP-184 Phase 1a Results Showing 54% Disease Control Rate In Heavily Pre-Treated Advanced Cancer Patients
Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform, Lowers Price Target to $60
Leerink Partners analyst Joseph Schwartz downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) from Outperform to Market Perform and lowers the price target from $82 to $60.
Ondas Autonomous Systems Subsidiary Selected As Prime Contractor On Behalf Of A Government Entity, With Initial Drone Purchase Order Anticipated In Jan.
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform, Raises Price Target to $16
Leerink Partners analyst Joseph Schwartz downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Market Perform and raises the price target from $15 to $16.
Alpha Modus Files Patent Infringement Lawsuit Against H&M Relating To Patents For In-Store AI And Retail Intelligence Systems
PolyPid Receives FDA Pre-NDA Meeting Minutes For D-PLEX₁₀₀ Supporting NDA Submission
USA Import Price Index (MoM) For Sept. Revises Prior From 0.3% To 0.1%
USA Import Price Index (MoM) For Sept. 0.0% Vs 0.1% Est.
Canada Labor Productivity (QoQ) (Q3) +0.9% vs +0.4% Est.
Export Price Index (MoM) Prior Revised From +0.3% To +0.1%
Export Price Index (MoM) (Sep) 0% vs +0.1% Est.
Arete Research Upgrades Lyft to Neutral, Raises Price Target to $20
Arete Research analyst Oliver Lester upgrades Lyft (NASDAQ:LYFT) from Sell to Neutral and raises the price target from $10 to $20.
Telsey Advisory Group Maintains Outperform on Dollar Tree, Maintains $130 Price Target
Telsey Advisory Group analyst Joseph Feldman maintains Dollar Tree (NASDAQ:DLTR) with a Outperform and maintains $130 price target.
Reported Earlier: 'Italy's doValue renews new bad loan management contract with Santander' - Reuters
ADP Reports November Hiring Was Particularly Weak In Manufacturing, Professional And Business Services, Information And Construction
Rosenblatt Maintains Buy on CrowdStrike Holdings, Maintains $630 Price Target
Rosenblatt analyst Catharine Trebnick maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Buy and maintains $630 price target.